23
Jun
2026
SCHIZOPHRENIA UPDATES 2025-2026
Posted On June 23, 2026
By [email protected]
And has No Comment
The Biggest Story — KarXT (Cobenfy®): The First Non-Dopaminergic Antipsychotic
September 2024: A Historic FDA Approval
Background:
- For 70+ years, ALL antipsychotics blocked dopamine D2 receptors
- This approach: good for positive symptoms, poor for negative/cognitive symptoms
- Side effects: EPS, tardive dyskinesia, metabolic syndrome, weight gain
The KarXT Revolution:
What Is It?
- Xanomeline: M1/M4 muscarinic acetylcholine receptor agonist (central)
- Trospium: Peripheral muscarinic antagonist (blocks GI side effects)
- Trade name: Cobenfy® (Bristol Myers Squibb, after Karuna acquisition)
- Mechanism: First antipsychotic that does NOT block dopamine
The Ingenious Solution:
- Xanomeline alone → effective centrally BUT severe GI side effects (abandoned in 1990s)
- Adding trospium (doesn’t cross BBB) → blocks peripheral side effects
- Result: Central efficacy maintained + tolerable side effect profile
Phase 3 EMERGENT Trial Results:
- PANSS total score improvement: 9.6-11.6 points vs. placebo (statistically significant)
- Improved BOTH positive AND negative symptom subscales
- No weight gain
- No significant EPS/tardive dyskinesia
- No metabolic side effects
- First antipsychotic to improve cognitive impairment significantly
Real-World Data (2025-2026):
- State hospital system effectiveness data published
- Effective in treatment-resistant cases
- Being integrated into clinical practice
- China NDA accepted (January 2025) — global expansion
December 2024 — Cognitive Improvement Confirmed:
- Pooled Phase 3 data (2 trials) confirmed significant cognitive improvement
- First antipsychotic to reliably improve cognitive impairment
- Published in the American Journal of Psychiatry
Current Studies (2026):
- ARISE Trial: Adjunctive use in inadequately controlled schizophrenia
- ADEPT-4: Alzheimer’s psychosis (Phase 3, 406 patients)
- New formulation development (enteric-coated capsule)
- Completion slated for late 2026
Iclepertin Failure — A Cautionary Tale (January 2025)
The Glutamate Hypothesis Setback
Background:
- Iclepertin (BI 425809) — glycine transporter 1 inhibitor
- Designed to improve cognitive impairment in schizophrenia
- Extensive Phase 2 promise
- The glutamate hypothesis target
January 2025: Phase 3 FAILURE
- Primary endpoint not met
- Cognitive improvement was not demonstrated
- Major blow to glutamatergic approach for cognition
- Billions in investment lost
Lessons Learned:
- Translational gap between Phase 2 and Phase 3
- Cognitive endpoints in schizophrenia very difficult
- Glutamatergic approach not abandoned but reassessed
- Need better biomarkers to select responders
Impact on Field:
- Renewed focus on muscarinic approach (KarXT success)
- Re-evaluation of glutamate target validation
- Importance of Phase 2 biomarker studies
- More rigorous translational science is required
Emraclidine — The Next Muscarinic Challenger
A New Mechanism: M4 Positive Allosteric Modulator
What Is Emraclidine?
- Selective M4 muscarinic receptor positive allosteric modulator (PAM)
- Different from KarXT’s direct M1/M4 agonism
- AbbVie development
- Only enhances M4 when endogenous acetylcholine binds (more selective)
Phase 1b Results (Lancet, 2022):
- Significant reduction in PANSS scores
- Well-tolerated
- Promising signal for efficacy
Phase 2 Results (November 2024 — Mixed):
- AbbVie provided an update with Phase 2 results
- Less definitive than hoped
- The program continues, but with recalibration
Significance:
- The second muscarinic approach is being developed
- May have better selectivity than KarXT
- Different side effect profile potentially
- Validating the muscarinic pathway as a target
Updated Schizophrenia Treatment Algorithm 2025-2026
New Treatment Landscape
First Episode Psychosis:
- Oral atypical antipsychotic (aripiprazole, risperidone, quetiapine)
- Consider KarXT (Cobenfy) especially if:
- Metabolic syndrome concerns
- Prior EPS/TD
- Cognitive impairment prominent
- Negative symptoms predominant
- Psychosocial interventions (CBT, family therapy, supported employment)
- Cognitive remediation early in treatment
Inadequate Response after 2 Adequate Trials:
5. Clozapine (remains the gold standard for TRS)
6. KarXT adjunctive (ARISE trial ongoing)
7. AI-guided pharmacogenomic selection
Negative Symptoms (Major Unmet Need):
- KarXT: Shows improvement in negative symptoms
- Adding antidepressants (SSRIs, mirtazapine)
- Cognitive remediation
- Supported employment
- Emraclidine (if approved)
Cognitive Impairment:
- KarXT: First medication with consistent cognitive benefit
- Cognitive remediation programs
- Exercise prescription
- Sleep optimization
Other 2025-2026 Research Updates
Biomarker Progress
Blood Biomarkers (JAMA Psychiatry 2025):
- White blood cell subpopulation differences confirmed in schizophrenia
- Systematic review and meta-analysis
- Potential diagnostic and monitoring biomarker
- More accessible than neuroimaging
Neuroimaging Advances:
- 3D CNN analysis of MRI (2025): 83% diagnostic accuracy
- Multimodal AI models approaching clinical utility
- Functional connectivity patterns characterize subtypes
Immune System in Schizophrenia
2025 Meta-Analysis Findings:
- Confirmed inflammatory pathways in schizophrenia
- Leukocyte subpopulation differences (JAMA Psychiatry 2025)
- Anti-inflammatory strategies in clinical trials
- Microbiome-gut-brain axis research expanding
Mortality in Schizophrenia
Ongoing Concern:
- Schizophrenia reduces life expectancy by 15-25 years
- Cardiovascular disease leading cause
- KarXT metabolic neutrality potentially life-extending
- Physical health monitoring must be a priority
Long-Acting Injectables (LAIs): Growing Evidence
New Long-Term Data:
- Monthly and 3-monthly formulations are accumulating more evidence
- Adherence significantly better than oral medications
- May be considered earlier in treatment (not just for non-adherence)
- AI monitoring of LAI administration schedules
Integrated AI + New Treatment Vision
How AI Enhances the New Treatment Landscape
AI + KarXT (Cobenfy):
- AI identifies patients most likely to benefit (negative/cognitive dominant)
- AI monitors muscarinic side effects (nausea, sweating)
- AI tracks cognitive improvement objectively
- AI-guided dose optimization
AI + Clozapine:
- Automated WBC monitoring and risk stratification
- Metabolic monitoring dashboard
- Seizure risk monitoring
- Enhanced safety through continuous surveillance
AI + Long-Acting Injectables:
- Adherence tracking between injections
- Digital phenotyping between monthly visits
- Relapse prediction despite LAI use
- Injection timing optimization
AI + Psychosocial Treatments:
- VR for social skills training
- AI-driven cognitive remediation
- Chatbot between therapy sessions
- Family psychoeducation apps
SLIDE 20: Saudi Arabia Context — Relevance to Your Practice
AI and Schizophrenia in the Arab World and KSA
Current Landscape in KSA:
- Vision 2030 includes digital health transformation
- Ministry of Health digital health strategy
- Telemedicine expansion post-COVID
- Growing interest in AI-assisted diagnosis
Specific Considerations for Saudi Practice:
Cultural Factors Affecting AI Deployment:
- Arabic language NLP models are less developed than English language models
- Symptom expression is culturally influenced
- The family-centered care model affects monitoring consent
- Religious and cultural context in psychoeducation
Practical Applications for DSFH:
- Digital phenotyping for outpatient monitoring
- AI-assisted medication adherence tracking
- Clozapine safety AI for TRS patients
- Telemedicine + AI for rural Saudi communities
- Arabic-language chatbots for patient education
Research Opportunities:
- Arab-specific AI training datasets needed
- Arabic NLP models for thought disorder detection
- Gulf region pharmacogenomics data
- Cultural adaptation of digital interventions
SLIDE 21: Conclusions and Future Directions
Summary: AI’s Transformative Impact on Schizophrenia Care
1. History Taking:
- Continuous digital phenotyping replaces episodic clinic visits
- Voice and speech AI detects subtle abnormalities
- Wearables provide objective behavioral data
2. Clinical Presentation:
- Objective negative and cognitive symptom measurement
- Standardized assessment independent of rater bias
- Real-time symptom monitoring
3. Diagnosis:
- AI approaches 90%+ accuracy (research settings)
- Multimodal biomarkers emerging
- Prodromal detection 2-3 years earlier
4. Management:
- Personalized medication selection via pharmacogenomics
- Adherence monitoring
- Relapse prediction 7-14 days in advance
- Cognitive and social rehabilitation apps
2025-2026 Treatment Highlights
- KarXT (Cobenfy®) — First non-dopaminergic antipsychotic, FDA approved September 2024, improves positive, negative, AND cognitive symptoms without metabolic burden
- Iclepertin failure — January 2025, glutamate approach cautionary tale
- Emraclidine — Phase 2 data, muscarinic M4 PAM under evaluation
- AI in schizophrenia rehabilitation — 83 studies mapped, symptom monitoring leading application
- Blood biomarkers — JAMA Psychiatry 2025 confirms immune differences
- Multimodal AI diagnosis — Approaching clinical utility (185 studies reviewed to March 2026)
The Bottom Line
“AI must be emphasized as an auxiliary tool, with clinical judgment and compassionate care from healthcare professionals remaining crucial. The in-depth integration of AI technology into clinical practice will advance the field of schizophrenia, ultimately improving quality of life and treatment outcomes of patients.” — Nature Schizophrenia, April 2026
Future Research Priorities
- Arabic-language and culturally diverse AI training data
- Functional rehabilitation AI applications (currently underrepresented)
- Long-term safety data for KarXT
- AI biomarkers guiding personalized treatment selection
- Ethical frameworks for AI in vulnerable psychiatric populations
- Combination AI + new pharmacology approaches
- Emraclidine Phase 3 trials
- Oveporexton (orexin agonist) for comorbid sleep disorders
References
- Nature Schizophrenia (2025, April 2026): “Can AI be the future solution to schizophrenia challenges?”
- Translational Psychiatry (March 2026): AI rehabilitation applications — systematic scoping review (83 studies)
- Frontiers in Psychiatry (May 2026): AI approaches for schizophrenia prediction — systematic review (185 studies)
- CNS Drugs (2026): New pharmacological approaches post-iclepertin landscape
- JAMA Psychiatry (2025): Blood leukocyte subpopulations in schizophrenia — meta-analysis
- American Journal of Psychiatry (December 2024): KarXT and cognitive impairment — pooled Phase 3 data
- Frontiers in Psychiatry (January 2026): Real-world effectiveness of xanomeline-trospium in a state hospital
- Scientific Reports (March 2026): Explainable AI for the schizophrenia prodromal phase
- European Psychiatry (2024): AI and VR in women with schizophrenia
- Frontiers in Psychiatry (2026): AI diagnostic model for schizophrenia in HIV
- ClinicalMetric (March 2026): Schizophrenia clinical trials 2026
- NeurologyLive (May 2026): Advances in orexin-based therapies
Prepared for: Department of Psychiatry, Dr. Soliman Fakeeh Hospital (DSFH) Author: [Dr. Serag] Date: June 2026 Website: seragpsych.com
